---
title: "Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: RAPIDe-2"
description: "Formulary evidence on Deucrictibant (PHA121, PHA-022121) in On-demand treatment of hereditary angioedema attacks: RAPIDe-2. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 55 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/clinical-evidence/rapide-2"
published: "2026-11-18T22:35:03-05:00"
modified: "2026-11-18T22:35:03-05:00"
---

# Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: RAPIDe-2

<a id="heading-3.1.3"></a>

## 3.1.3 RAPIDe-2

<a id="heading-3.1.3.1"></a>

### 3.1.3.1 Objective

<a id="topic-3.1.3.1-1"></a>

#### Registry objective: long-term safety and efficacy of on-demand treatment

> “This study evaluates the safety and efficacy of long-term on-demand treatment with orally administered deucrictibant for acute hereditary angioedema (HAE) attacks, including laryngeal attacks.”

Source: [ClinicalTrials.gov NCT05396105](https://clinicaltrials.gov/study/NCT05396105)

<a id="topic-3.1.3.1-2"></a>

#### Main and secondary objectives in the EU register record

> “To evaluate the safety of long-term on-demand treatment with PHA-022121 for acute hereditary angioedema (HAE) attacks including laryngeal attacks.”
> “To evaluate the maintenance of PHA-022121 efficacy in achieving symptom relief for any subsequent acute HAE attacks including laryngeal attacks,”
> “To evaluate the proportion of PHA-022121-treated attacks requiring a second dose of PHA-022121 to achieve symptom relief.”

Source: [EU Clinical Trials Register 2021-006906-58](https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-006906-58/ES)

<a id="topic-3.1.3.1-3"></a>

#### Objective of the Part A final analysis

> “To evaluate the long-term safety and efficacy of deucrictibant immediate-release (IR) capsule for on-demand treatment of repeat HAE attacks in the RAPIDe-2 extension study.”

Source: [Anderson et al. (2025a)](https://ir.pharvaris.com/static-files/60147f58-a8d1-42ef-830f-681322e0be54)

<a id="topic-3.1.3.1-4"></a>

#### Objective of the post hoc upper airway and laryngeal attack analysis

> “Evaluate the safety and efficacy of deucrictibant immediate-release (IR) capsule for on-demand treatment of upper airway, including laryngeal, HAE attacks.”

Source: [Anderson et al. (2025b)](https://ir.pharvaris.com/static-files/2f27144c-943d-44d3-8994-259620304029)

<a id="topic-3.1.3.1-5"></a>

#### Objective of the post hoc durability-of-response analysis

> “To assess the durability of effects following a single dose of deucrictibant immediate-release (IR) capsule for treatment of HAE attacks in the placebo-controlled RAPIDe-1 trial (NCT04618211)* and in the RAPIDe-2 open-label long-term extension study (NCT05396105)*.”

Source: [Jacobs et al. (2025)](https://ir.pharvaris.com/static-files/0dcd8b83-ac4a-4fed-8d4e-632df4720b2c)

<a id="topic-3.1.3.1-6"></a>

#### Purpose stated by the company

> “In addition, we are also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

<a id="heading-3.1.3.2"></a>

### 3.1.3.2 Location and Study Date

<a id="topic-3.1.3.2-1"></a>

#### Registry dates, status, and number of locations

| Field | Reported value |
| --- | --- |
| Recruitment status | “Enrolling by invitation” |
| Study start (actual) | “2022-12-28” |
| Primary completion (estimated) | “2027-06” |
| Study completion (estimated) | “2027-06” |
| First posted | “2022-05-31” |
| Last update posted | “2026-07-21” |
| Locations | “This study has 60 locations” |

Source: [ClinicalTrials.gov NCT05396105](https://clinicaltrials.gov/study/NCT05396105)

<a id="topic-3.1.3.2-2"></a>

#### Sites anticipated in the European Economic Area

> “Number of sites anticipated in the EEA”
> “13”

Source: [EU Clinical Trials Register 2021-006906-58](https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-006906-58/ES)

<a id="topic-3.1.3.2-3"></a>

#### Study status in the annual report

> “The RAPIDe-2 study is still ongoing.”
> “Phase 2/3, Extension Study to evaluate the safety of long-term on-demand treatment with deucrictibant for acute HAE attacks”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

<a id="heading-3.1.3.3"></a>

### 3.1.3.3 Study Design

<a id="topic-3.1.3.3-1"></a>

#### Registry design details

| Field | Reported value |
| --- | --- |
| Phase | “Phase 2” and “Phase 3” |
| Allocation | “N/A” |
| Interventional model | “Single Group Assignment” |
| Masking | “None (Open Label)” |

Source: [ClinicalTrials.gov NCT05396105](https://clinicaltrials.gov/study/NCT05396105)

<a id="topic-3.1.3.3-2"></a>

#### Two parts: dose-blinded Part A and open-label Part B

> “Part A of the study will enroll adult participants from Study PHA022121-C201. The double-blind treatment assignment from Study PHA022121-C201 will be maintained.”
> “Part B is open-label treatment and includes participants rolling over from Part A, participants from Study PHA022121-C201 who did not participate in Part A, participants aged 12 years and older with HAE type I, type II, or HAE-nC1INH rolling over from Study PHA022121-C306, and deucrictibant treatment naïve adult participants with HAE-nC1INH who elect to participate in this extension study and meet the eligibility requirements.”

Source: [ClinicalTrials.gov NCT05396105](https://clinicaltrials.gov/study/NCT05396105)

<a id="topic-3.1.3.3-3"></a>

#### Part A design and treatment of upper airway attacks

> “In Part A of RAPIDe-2, participants remained blinded to their dose of deucrictibant (10 mg, 20 mg, 30 mg) but were able to treat every attack with active study drug. In the extension study, participants were able to treat upper airway attacks, including laryngeal attacks.”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

<a id="topic-3.1.3.3-4"></a>

#### Phase 2/3 long-term extension with scheduled assessments

> “a two-part, Phase 2/3 long-term extension study.”
> “Data collection: pre-specified at pre-treatment, hourly for 6 hours, and at 8, 12, 24, and 48 hours post-treatment.”

Source: [Anderson et al. (2025a)](https://ir.pharvaris.com/static-files/60147f58-a8d1-42ef-830f-681322e0be54)

<a id="topic-3.1.3.3-5"></a>

#### Study code: C303 in the registry, C201 in one annual report heading

> “PHA022121-C303”

Source: [ClinicalTrials.gov NCT05396105](https://clinicaltrials.gov/study/NCT05396105)

> “RAPIDe-2 Phase 2/3 On-Demand Long-Term Extension (C201)”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

<a id="heading-3.1.3.4"></a>

### 3.1.3.4 Eligibility Criteria

<a id="topic-3.1.3.4-1"></a>

#### Part A: adults who completed RAPIDe-1, without long-term prophylaxis

> “Part A eligible participants: adults who completed RAPIDe-1 (NCT04618211).”
> “Part A prophylaxis: no long-term HAE prophylaxis treatment was allowed. Recent use of long-term HAE prophylaxis treatment prior to screening was allowed provided a pre-specified washout period was observed.”

Source: [Anderson et al. (2025a)](https://ir.pharvaris.com/static-files/60147f58-a8d1-42ef-830f-681322e0be54)

<a id="topic-3.1.3.4-2"></a>

#### Registry inclusion: participants from RAPIDe-1 and RAPIDe-3, including adolescents

> “For participants from Study C201, received at least one dose of study drug (including the non-attack visit) in Study C201. For participants from Study C306, participant was randomized (and for adolescent participants ≥12 to <18 years received a dose of study drug in a non-attack state at Visit 1) and completed Study C306, with 2 attacks treated, or after closure of that study by the Sponsor.”
> “12 Years and older”

Source: [ClinicalTrials.gov NCT05396105](https://clinicaltrials.gov/study/NCT05396105)

<a id="topic-3.1.3.4-3"></a>

#### Registry inclusion: treatment-naive adults with HAE with normal C1 inhibitor

> “Adult participants with HAE type III (HAE-nC1INH) who are deucrictibant-treatment naïve, must meet all of the following:”
> “Documented effective attack symptom relief with on-demand icatibant treatment.”
> “A history of at least 1 HAE attack in the last 3 months prior to Screening”

Source: [ClinicalTrials.gov NCT05396105](https://clinicaltrials.gov/study/NCT05396105)

<a id="topic-3.1.3.4-4"></a>

#### Registry exclusion: lanadelumab, washout periods, and strong CYP3A4 modulators

> “Use of lanadelumab for long-term HAE prophylactic therapy within 12 weeks prior to enrollment in Part A.”
> “2-week washout period before enrollment should be respected for participants who have used any C1-INH product, oral kallikrein inhibitors, attenuated androgens, or anti-fibrinolytics for long-term prophylactic HAE therapy.”
> “Use of concomitant medications that are strong CYP3A4 inhibitors (e.g., clarithromycin, erythromycin, itraconazole, ketoconazole, ritonavir) or strong CYP3A4 inducers (e.g., carbamazepine and phenytoin).”

Source: [ClinicalTrials.gov NCT05396105](https://clinicaltrials.gov/study/NCT05396105)

<a id="topic-3.1.3.4-5"></a>

#### Part B: stable long-term prophylaxis permitted

> “If a participant is receiving long-term prophylactic therapy with a medication indicated for HAE:, eg, plasma-derived C1INH, danazol at less than or equal to 200 mg/day, antifibrinolytics, berotralstat, or lanadelumab, they must be on a stable dose and regimen for at least 3 months before screening and intends to remain on the same dose for the duration of the study.”

Source: [ClinicalTrials.gov NCT05396105](https://clinicaltrials.gov/study/NCT05396105)

<a id="topic-3.1.3.4-6"></a>

#### EU register exclusion: QTcF prolongation

> “Presence of any medical condition that could interfere with the assessment of safety or efficacy or negatively affect the patient’s safety, including clinically significant abnormal ECG, most notably a QTcF > 470 ms (for females) or > 450 ms (for males), cardiovascular disease, abnormal liver function and abnormal kidney function.”

Source: [EU Clinical Trials Register 2021-006906-58](https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-006906-58/ES)

<a id="heading-3.1.3.5"></a>

### 3.1.3.5 Treatment

<a id="topic-3.1.3.5-1"></a>

#### Registry arms: blinded dose in Part A, open-label soft capsules in Part B

> “Participants will receive the dose of deucrictibant they were randomized to in the PHA022121-C201 study (low, medium, or high dose, each consisting of 3 capsules of deucrictibant or matching placebo) for oral use for on-demand treatment of HAE attacks.”
> “Participants will receive deucrictibant soft capsules for oral use for on-demand treatment of HAE attacks.”

Source: [ClinicalTrials.gov NCT05396105](https://clinicaltrials.gov/study/NCT05396105)

<a id="topic-3.1.3.5-2"></a>

#### Second dose and rescue medication rules

> “In RAPIDe-2, a second dose was permitted ≥4 hours after first dose if symptoms persisted or progressed. If symptoms still persisted or progressed after the second dose, rescue medication was permitted. For upper airway attacks with inadequate response or symptom recurrence ≥4 hours after first dose, only rescue medication was permitted.”

Source: [Jacobs et al. (2025)](https://ir.pharvaris.com/static-files/0dcd8b83-ac4a-4fed-8d4e-632df4720b2c)

<a id="topic-3.1.3.5-3"></a>

#### Part A results: combined dose group of 10, 20, and 30 mg

> “Data for combined dose group shown (deucrictibant 10 mg, 20 mg, and 30 mg).”

Source: [Anderson et al. (2025a)](https://ir.pharvaris.com/static-files/60147f58-a8d1-42ef-830f-681322e0be54)

<a id="heading-3.1.3.6"></a>

### 3.1.3.6 Study Outcomes

<a id="heading-3.1.3.6.1"></a>

#### 3.1.3.6.1 Rationale for Using Treatment-emergent Adverse Events as the Primary Endpoint

<a id="topic-3.1.3.6.1-1"></a>

##### Primary endpoint: long-term safety of on-demand use

> “The primary endpoint of the study is to evaluate the long-term safety of deucrictibant as an on-demand agent; secondary endpoints of efficacy were measured using patient global impression of change (PGI-C) and patient global impress of severity (PGI-S) patient reported outcome (PRO) scales.”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

<a id="topic-3.1.3.6.1-2"></a>

##### Registry primary outcome measures and time frame

> “Treatment-emergent Adverse Events (TEAEs), treatment-related TEAEs, treatment-emergent serious adverse events (TESAEs), treatment-related TESAEs, and TEAEs leading to deucrictibant discontinuation”
> “From enrollment through study completion, up to 54 months (dependent on time of enrollment).”
> “Descriptive in nature, no formal statistical hypothesis testing will be performed.”

Source: [ClinicalTrials.gov NCT05396105](https://clinicaltrials.gov/study/NCT05396105)

<a id="topic-3.1.3.6.1-3"></a>

##### Safety components of the primary endpoint

> “Primary endpoint: safety, including treatment-emergent adverse events (TEAEs), clinical laboratory tests, vital signs, and electrocardiogram (ECG) findings.”
> “Secondary endpoints: efficacy endpoints using patient-reported outcome tools.”

Source: [Anderson et al. (2025a)](https://ir.pharvaris.com/static-files/60147f58-a8d1-42ef-830f-681322e0be54)

<a id="topic-3.1.3.6.1-4"></a>

##### Secondary endpoints in the registry

> “Time to onset of symptom relief, defined as Patient Global Impression of Change (PGI-C) rating of at least "a little better" for 2 consecutive timepoints within 12 hours post-treatment”
> “Time to substantial symptom relief by Patient Global Impression of Severity (PGI-S), defined as achieving ≥1 point reduction in PGI-S from pre-treatment for 2 consecutive timepoints within 12 hours post-treatment”
> “Proportion of deucrictibant-treated attacks requiring rescue medication within 24 hours post-treatment”
> “Time to onset of symptom relief, assessed by a ≥30% reduction in VAS-3/ VAS-5 (Part A) or AMRA (Part B) composite score from the pre-treatment score”

Source: [ClinicalTrials.gov NCT05396105](https://clinicaltrials.gov/study/NCT05396105)

<a id="topic-3.1.3.6.1-5"></a>

##### Censoring rules for rescue medication

> “If rescue medication used within 14.5 hours post-treatment, time to event was censored at 14.5 hours regardless of whether event occurred within 12 hours post-treatment.”
> “Rescue medication use within 33.5 hours post-treatment was regarded as not achieving complete attack resolution at 24 hours.”

Source: [Anderson et al. (2025a)](https://ir.pharvaris.com/static-files/60147f58-a8d1-42ef-830f-681322e0be54)

<a id="topic-3.1.3.6.1-6"></a>

##### Post hoc endpoint: durability of response and symptom reoccurrence

> “Durability of treatment response: the achievement and maintenance of serial milestones of symptom relief and resolution without reoccurrence of symptoms following a single dose of deucrictibant only.”
> “Symptom reoccurrence: following the achievement of each efficacy milestone, symptom reoccurrence was evaluated as any instance where the milestone was no longer being met within 24 hours.”

Source: [Anderson et al. (2025a)](https://ir.pharvaris.com/static-files/60147f58-a8d1-42ef-830f-681322e0be54)

<a id="topic-3.1.3.6.1-7"></a>

##### Post hoc definition of upper airway attacks

> “Upper airway attacks confirmed by investigators as per protocol definition if following manifestations of an attack were reported: swelling of the lips/tongue or any sensation of lump in the throat, difficulty swallowing, or voice change.”
> “Difficulty swallowing and voice change as manifestations of an attack were assessed prior to treatment using the 5-symptom composite Angioedema syMptom Rating scAle (AMRA-5).”

Source: [Anderson et al. (2025b)](https://ir.pharvaris.com/static-files/2f27144c-943d-44d3-8994-259620304029)

<a id="heading-3.1.3.7"></a>

### 3.1.3.7 Statistical Analysis Description

<a id="heading-3.1.3.7.1"></a>

#### 3.1.3.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.3.7.1-1"></a>

##### Planned enrollment in the registry

> “Enrollment (Estimated)”
> “150”

Source: [ClinicalTrials.gov NCT05396105](https://clinicaltrials.gov/study/NCT05396105)

<a id="topic-3.1.3.7.1-2"></a>

##### Planned number of participants in the EU register record

> “Planned number of subjects to be included”
> “In the whole clinical trial”
> “72”

Source: [EU Clinical Trials Register 2021-006906-58](https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-006906-58/ES)

<a id="topic-3.1.3.7.1-3"></a>

##### Part A analyzed: 465 attacks in 19 participants

> “RAPIDe-2 Part A included 465 attacks from 19 participants.”

Source: [Anderson et al. (2025a)](https://ir.pharvaris.com/static-files/60147f58-a8d1-42ef-830f-681322e0be54)

> “RAPIDe-2 includes 465 attacks from 19 participants, 14 of the attacks were upper airway attacks.”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

<a id="topic-3.1.3.7.1-4"></a>

##### Upper airway attacks: 14 attacks in seven participants

> “465 attacks were treated by 19 participants.”
> “14 upper airway attacks, including laryngeal, were treated for seven participants.”
> “Difficulty in swallowing and/or voice change were reported as manifestations of six attacks prior to treatment.”

Source: [Anderson et al. (2025b)](https://ir.pharvaris.com/static-files/2f27144c-943d-44d3-8994-259620304029)

<a id="heading-3.1.3.7.2"></a>

#### 3.1.3.7.2 Description of Analysis Sets

<a id="topic-3.1.3.7.2-1"></a>

##### Safety and modified intention-to-treat analysis sets (Part A)

> “Participants who received at least one dose of deucrictibant IR capsule in the study.”
> “Modified intention-to-treat analysis set: participants who treated at least one attack with deucrictibant IR capsule and non-missing Patient Global Impression of Change (PGI-C) results from at least one post-treatment timepoint.”

Source: [Anderson et al. (2025a)](https://ir.pharvaris.com/static-files/60147f58-a8d1-42ef-830f-681322e0be54)

<a id="topic-3.1.3.7.2-2"></a>

##### Evaluable attacks for PGI-C and PGI-S endpoints

> “457 attacks have ≥1 post-treatment PGI-C result.”
> “449 attacks have non-missing pre-treatment PGI-S and ≥1 post-treatment PGI-S.”
> “Within-participant correlation was not accounted for in all Kaplan–Meier estimates.”

Source: [Anderson et al. (2025a)](https://ir.pharvaris.com/static-files/60147f58-a8d1-42ef-830f-681322e0be54)

<a id="topic-3.1.3.7.2-3"></a>

##### Baseline values carried from RAPIDe-1

> “Study baseline refers to results at the screening or enrollment visit of RAPIDe-2 Part A. For parameters whose values remain constant over time, baseline values from RAPIDe-1 were used.”

Source: [Anderson et al. (2025a)](https://ir.pharvaris.com/static-files/60147f58-a8d1-42ef-830f-681322e0be54)

<a id="heading-3.1.3.8"></a>

### 3.1.3.8 Results

<a id="heading-3.1.3.8.1"></a>

#### 3.1.3.8.1 Participant Disposition

<a id="topic-3.1.3.8.1-1"></a>

##### Entry from RAPIDe-1

> “Following treatment of participation in RAPIDe-1, participants were eligible to either join the Phase 2 randomized clinical trial of deucrictibant for the prevention of HAE attacks (CHAPTER-1) or roll over to the long-term extension on-demand study (RAPIDe-2).”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

<a id="topic-3.1.3.8.1-2"></a>

##### Part A: no discontinuations, withdrawals, or deaths due to adverse events

> “The final RAPIDe-2 Part A results included 465 HAE attacks treated with deucrictibant by 19 participants.”

Source: [Jacobs et al. (2025)](https://ir.pharvaris.com/static-files/0dcd8b83-ac4a-4fed-8d4e-632df4720b2c)

> “No TEAEs leading to treatment discontinuation, study withdrawal, or death.”

Source: [Anderson et al. (2025a)](https://ir.pharvaris.com/static-files/60147f58-a8d1-42ef-830f-681322e0be54)

<a id="heading-3.1.3.8.2"></a>

#### 3.1.3.8.2 Baseline Characteristics

<a id="topic-3.1.3.8.2-1"></a>

##### Part A participants, combined dose group (N=19)

| Characteristic | Deucrictibant IR capsule, combined dose group |
| --- | --- |
| Age in years, mean (SD) | “44.4 (17.6)” |
| Sex: male / female, n (%) | “7 (36.8) / 12 (63.2)” |
| Race: White / other, n | “18 / 1” |
| BMI, mean (SD) | “26.8 (4.0)” |
| Years since HAE diagnosis, mean (SD) | “23.3 (15.2)” |
| HAE-1, n (%) | “17 (89.5)” |
| HAE-2, n (%) | “2 (10.5)” |

Source: [Anderson et al. (2025a)](https://ir.pharvaris.com/static-files/60147f58-a8d1-42ef-830f-681322e0be54)

<a id="topic-3.1.3.8.2-2"></a>

##### Participants with and without upper airway attacks

| Characteristic | With ≥1 upper airway attack (n=7) | Without upper airway attacks (n=12) |
| --- | --- | --- |
| Age in years, mean (SD) | “46.0 (19.5)” | “43.4 (17.2)” |
| Sex: male / female, n (%) | “4 (57) / 3 (43)” | “3 (25) / 9 (75)” |
| Race: White / other, n | “7 / 0” | “11 / 1” |
| BMI, mean (SD) | “27.1 (3.8)” | “26.7 (4.2)” |
| Years since HAE diagnosis, mean (SD) | “20.8 (18.9)” | “24.7 (13.3)” |
| HAE-1, n (%) | “6 (85.7)” | “11 (91.7)” |
| HAE-2, n (%) | “1 (14.3)” | “1 (8.3)” |

Source: [Anderson et al. (2025b)](https://ir.pharvaris.com/static-files/2f27144c-943d-44d3-8994-259620304029)

<a id="heading-3.1.3.8.3"></a>

#### 3.1.3.8.3 Efficacy Results

<a id="topic-3.1.3.8.3-1"></a>

##### Median time to key efficacy endpoints, Part A (465 attacks)

| Endpoint | Median time | 95% CI |
| --- | --- | --- |
| Onset of symptom relief (PGI-C) | “1.1 hours” | “(1.0, 1.1)” |
| Substantial symptom relief (PGI-C) | “2.5 hours” | “(2.1, 2.9)” |
| Reduction in attack severity (PGI-S) | “2.8 hours” | “(2.3, 2.9)” |
| Complete attack resolution (PGI-S) | “10.6 hours” | “(8.5, 11.5)” |

Source: [Anderson et al. (2025a)](https://ir.pharvaris.com/static-files/60147f58-a8d1-42ef-830f-681322e0be54)

<a id="topic-3.1.3.8.3-2"></a>

##### Median times reported in the annual report

> “Secondary endpoints from the RAPIDe-2 study included time to onset of symptom relief as measured by a PGI-C rating of at least “a little better” for two consecutive timepoints (1.1 hours), time to substantial symptom relief as measured by a PGI-C rating of at least “better” for two consecutive timepoints (2.5 hours), time to reduction in attack severity as measured by at least one level reduction in PGI-S from pre-treatment for two consecutive endpoints (2.8 hours), and time to complete attack resolution as measured by a PGI-S rating of “none” (10.6 hours).”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

<a id="topic-3.1.3.8.3-3"></a>

##### Proportion of attacks achieving key endpoints, evaluable attacks (457 PGI-C, 449 PGI-S)

| Endpoint | Proportion of attacks | Attacks |
| --- | --- | --- |
| Onset of symptom relief by 12 hours | “97.8%” | “447/457” |
| Substantial symptom relief by 12 hours | “95.2%” | “435/457” |
| Reduction in attack severity by 12 hours | “96.7%” | “434/449” |
| Complete symptom resolution at 24 hours | “86.9%” | “390/449” |

Source: [Anderson et al. (2025a)](https://ir.pharvaris.com/static-files/60147f58-a8d1-42ef-830f-681322e0be54)

<a id="topic-3.1.3.8.3-4"></a>

##### Attacks treated with a single dose and rescue medication use, evaluable attacks (457)

| Attacks | One dose | Two doses |
| --- | --- | --- |
| Overall | “86.2%” “394/457” | “13.8%” “63/457” |
| Complete attack resolution within 24 hours | “89.2%” “348/390” | “10.8%” “42/390” |

Source: [Anderson et al. (2025a)](https://ir.pharvaris.com/static-files/60147f58-a8d1-42ef-830f-681322e0be54)

> “8 attacks used rescue medication within 24 hours post-treatment.”

Source: [Anderson et al. (2025a)](https://ir.pharvaris.com/static-files/60147f58-a8d1-42ef-830f-681322e0be54)

<a id="topic-3.1.3.8.3-5"></a>

##### Attacks treated with a single dose, all treated attacks (465)

> “of attacks were treated with a single dose of deucrictibant IR capsule in RAPIDe-2”
> “84.9%”
> “(395/465)”

Source: [Jacobs et al. (2025)](https://ir.pharvaris.com/static-files/0dcd8b83-ac4a-4fed-8d4e-632df4720b2c)

<a id="topic-3.1.3.8.3-6"></a>

##### Durability of response after a single dose, post hoc analysis

> “98.3% (344/350)”
> “of attacks achieving onset of symptom relief with a single dose of deucrictibant maintained a durable response”
> “99.2% (382/385)”
> “of attacks achieving complete attack resolution with a single dose of deucrictibant maintained a durable response”

Source: [Anderson et al. (2025a)](https://ir.pharvaris.com/static-files/60147f58-a8d1-42ef-830f-681322e0be54)

> “of attacks that achieved symptom relief and resolution with 1 deucrictibant IR capsule had a durable response without symptom reoccurrence in RAPIDe-2”

Source: [Jacobs et al. (2025)](https://ir.pharvaris.com/static-files/0dcd8b83-ac4a-4fed-8d4e-632df4720b2c)

<a id="topic-3.1.3.8.3-7"></a>

##### Upper airway attacks compared with non-upper airway attacks, post hoc analysis

| Endpoint | Upper airway attacks (n=7 participants) | Non-upper airway attacks in participants with upper airway attacks (n=7) | All non-upper airway attacks (n=19) |
| --- | --- | --- | --- |
| Total number of attacks treated | “14” | “177” | “451” |
| Time to onset of symptom relief, median hours (95% CI) | “1.4 (0.8–3.0)” | “1.0 (1.0–1.2)” | “1.1 (1.0–1.1)” |
| Time to substantial symptom relief, median hours (95% CI) | “3.6 (2.0–6.1)” | “2.7 (2.1–3.0)” | “2.4 (2.1–2.8)” |
| Time to reduction in attack severity, median hours (95% CI) | “1.8 (0.9–3.0)” | “2.1 (2.0–2.8)” | “2.8 (2.4–2.9)” |
| Time to complete attack resolution, median hours (95% CI) | “8.9 (3.9–36.3)” | “8.0 (7.3–10.7)” | “10.6 (8.5–11.5)” |

Source: [Anderson et al. (2025b)](https://ir.pharvaris.com/static-files/2f27144c-943d-44d3-8994-259620304029)

<a id="topic-3.1.3.8.3-8"></a>

##### Upper airway attacks: proportions achieving endpoints, single dose, and rescue use

> “of upper airway attacks achieved onset of symptom relief by 12 hours”
> “of upper airway attacks achieved complete attack resolution at 24 hours”
> “8/12”
> “of upper airway attacks were treated with a single dose of deucrictibant IR capsule”
> “One participant used rescue medication for one upper airway attack and used a single dose of deucrictibant to treat 2 subsequent upper airway attacks.”

Source: [Anderson et al. (2025b)](https://ir.pharvaris.com/static-files/2f27144c-943d-44d3-8994-259620304029)

<a id="topic-3.1.3.8.3-9"></a>

##### Company summary of Part A efficacy

> “In the upper airway attacks treated, there were similar times to relief and resolution of attacks as seen in the full data set. The majority of the attacks were treated with a single dose of deucrictibant and without rescue medication within 24 hours. The final results from Part A of the RAPIDe-2 extension were consistent with the Phase 2 RAPIDe-1 study and provide evidence on the long-term safety and efficacy of deucrictibant IR capsule for treatment of repeat HAE attacks.”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

<a id="heading-3.1.3.8.4"></a>

#### 3.1.3.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.3.8.5"></a>

#### 3.1.3.8.5 Safety Results

<a id="topic-3.1.3.8.5-1"></a>

##### Adverse events within 3 days of study drug, Part A (N=19; 465 attacks)

| Adverse events | Deucrictibant IR capsule, combined dose group |
| --- | --- |
| Attacks with any TEAE, n (%) | “12 (2.6)” |
| Treatment-related TEAEs, n | “0” |
| Serious TEAEs, n | “1” |
| Treatment-related serious TEAEs, n | “0” |
| TEAEs leading to study drug discontinuation, study withdrawal, or death, n | “0” |

Source: [Anderson et al. (2025a)](https://ir.pharvaris.com/static-files/60147f58-a8d1-42ef-830f-681322e0be54)

<a id="topic-3.1.3.8.5-2"></a>

##### Serious adverse event unrelated to treatment, and laboratory, vital sign, and ECG findings

> “Tooth caries unrelated to treatment.”
> “No treatment-related TEAEs.”
> “No treatment-related serious or severe TEAEs, no treatment-related TEAEs in laboratory parameters, vital signs, or ECG findings.”

Source: [Anderson et al. (2025a)](https://ir.pharvaris.com/static-files/60147f58-a8d1-42ef-830f-681322e0be54)

<a id="topic-3.1.3.8.5-3"></a>

##### Safety across dose groups in the annual report

> “Deucrictibant was well tolerated across all doses, with no treatment-related treatment-emergent adverse events (TEAEs), with no TEAEs leading to treatment discontinuation, study withdrawal, or death.”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

<a id="topic-3.1.3.8.5-4"></a>

##### Safety in upper airway and non-upper airway attacks

> “Deucrictibant was generally well tolerated with no treatment-related TEAEs reported across upper airway and non-upper airway attacks.”

Source: [Anderson et al. (2025b)](https://ir.pharvaris.com/static-files/2f27144c-943d-44d3-8994-259620304029)

<a id="heading-3.1.3.9"></a>

### 3.1.3.9 Study Limitations

<a id="topic-3.1.3.9-1"></a>

#### Summary

- RAPIDe-2 is a single-group study with no control arm, and its registry record lists no masking. In Part A, participants were blinded to dose while every attack was treated with active drug. The registry states the primary safety analysis is “Descriptive in nature, no formal statistical hypothesis testing will be performed”.
- Part A included 19 adults, all from RAPIDe-1, who contributed 465 attacks; long-term prophylaxis was not allowed and 18 of the 19 were White. Results were reported for the combined 10 mg, 20 mg, and 30 mg dose group.
- Denominators vary by endpoint: 457 attacks had post-treatment PGI-C data and 449 had pre-treatment and post-treatment PGI-S data, and the single-dose proportion is reported as 394/457 and as 395/465. “Within-participant correlation was not accounted for in all Kaplan–Meier estimates”.
- Upper airway results rest on 14 attacks in seven participants.
- Rescue medication use within 14.5 hours led to censoring at 14.5 hours, and baseline values for constant parameters were taken from RAPIDe-1.
- Planned enrollment is 150 in ClinicalTrials.gov and 72 in the EU register. “The RAPIDe-2 study is still ongoing”, with primary completion estimated for 2027-06. Part A results come from documents on the company's investor website and the company's annual report, and Part B results are limited to cardiovascular events in 110 participants.

Source: [ClinicalTrials.gov NCT05396105](https://clinicaltrials.gov/study/NCT05396105); [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm); [Anderson et al. (2025a)](https://ir.pharvaris.com/static-files/60147f58-a8d1-42ef-830f-681322e0be54); [Jacobs et al. (2025)](https://ir.pharvaris.com/static-files/0dcd8b83-ac4a-4fed-8d4e-632df4720b2c); [Anderson et al. (2025b)](https://ir.pharvaris.com/static-files/2f27144c-943d-44d3-8994-259620304029); [EU Clinical Trials Register 2021-006906-58](https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-006906-58/ES); [Lesage et al. (2026a)](https://ir.pharvaris.com/static-files/832a8830-6fd1-41ac-b767-e1b348388853)

## Related pages
- [Deucrictibant (PHA121): On-demand treatment of hereditary angioedema attacks](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Terms and abbreviations](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/terms-and-abbreviations.md)
- [Deucrictibant (PHA121): On-demand treatment of hereditary angioedema attacks](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/executive-summary) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/executive-summary.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Product information and disease description](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Clinical evidence](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/clinical-evidence.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Economic information and modeling report](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/economics) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/economics.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: References](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/references) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/references.md)
